PCDHGA12: A Potential Drug Target and Biomarker for Parkinson's Disease

Target Name: PCDHGA12

NCBI ID: G26025

PCDHGA12

PCDHGA12: A Potential Drug Target and Biomarker for Parkinson's Disease

Parkinson's disease is a neurodegenerative disorder that is characterized by symptoms such as tremors, rigidity, and difficulty with movement. It is a degenerative brain disorder that affects millions of people worldwide, and its symptoms can gradually worsen over time. Despite the development of sophisticated treatments, the underlying cause of Parkinson's disease remains unresolved, and there is a high demand for new and effective therapies.

The protein PCDHGA12 has emerged as a promising drug target and biomarker for Parkinson's disease. PCDHGA12 is a protein that is expressed in the brain and is involved in the development and progression of Parkinson's disease. Studies have shown that PCDHGA12 levels are significantly decreased in the brains of people with Parkinson's disease, and that overexpression of PCDHGA12 has been shown to exacerbate the symptoms of the disease.

The exact role of PCDHGA12 in the development and progression of Parkinson's disease is not yet fully understood, but it is thought to play a key role in the regulation of dopamine levels in the brain. Dopamine is a neurotransmitter that is involved in motor function and is one of the primary targets of Parkinson's disease. Studies have shown that PCDHGA12 is involved in the regulation of dopamine levels, and that alterations in dopamine levels are a hallmark of Parkinson's disease.

One of the key challenges in the development of new treatments for Parkinson's disease is the difficulty of targeting the brain without causing harm to other parts of the body. This is because the brain is a complex and delicate system, and any changes that occur in the brain can have serious consequences for the entire body. To address this challenge, researchers have turned to PCDHGA12 as a potential drug target and biomarker for Parkinson's disease.

PCDHGA12 has been shown to be involved in the regulation of dopamine levels in the brain, and this makes it an attractive target for drug development. Studies have shown that PCDHGA12 is involved in the production and degradation of dopamine, and that alterations in dopamine levels can be caused by changes in PCDHGA12 levels. This suggests that targeting PCDHGA12 may be a way to reduce dopamine levels in the brain and alleviate the symptoms of Parkinson's disease.

Another potential mechanism by which PCDHGA12 may contribute to the development and progression of Parkinson's disease is its role in the regulation of neurotransmitter release. Studies have shown that PCDHGA12 is involved in the regulation of neurotransmitter release from the brain, and that changes in neurotransmitter release can be a hallmark of Parkinson's disease. This suggests that PCDHGA12 may be involved in the regulation of dopamine release from the brain, and that alterations in dopamine release can contribute to the symptoms of Parkinson's disease.

In conclusion, PCDHGA12 is a protein that is involved in the development and progression of Parkinson's disease. Studies have shown that PCDHGA12 levels are significantly decreased in the brains of people with Parkinson's disease, and that overexpression of PCDHGA12 has been shown to exacerbate the symptoms of the disease. The exact role of PCDHGA12 in the regulation of dopamine levels and neurotransmitter release is not yet fully understood, but it is thought to play a key role in the development and progression of Parkinson's disease. Targeting PCDHGA12 with drugs may be a promising new approach to the treatment of Parkinson's disease.

Protein Name: Protocadherin Gamma Subfamily A, 12

Functions: Potential calcium-dependent cell-adhesion protein. May be involved in the establishment and maintenance of specific neuronal connections in the brain

The "PCDHGA12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PCDHGA12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets